Court Finds United Therapeutics Caused $137 Million Loss to Liquidia; Yutrepia Market Warning

A court has found that United Therapeutics' interference with the launch of a generic Treprostinil injection caused losses of more than $137 million to Liquidia Technologies. This ruling serves as a warning to United Therapeutics once Liquidia's Yutrepia comes to market.